Global market sentiment for 2026
As we step into 2026, the health industries sector is characterized by cautious optimism, supported by the anticipation of easing interest rates alongside robust therapeutic pipelines and ongoing innovation in digital health. Yet, market volatility persists, driven by selective buyer appetite and lingering uncertainties around regulatory frameworks, pricing pressures, and macroeconomic conditions.
Investors remain focused on mature, revenue-generating companies rather than earlier-stage ventures, emphasizing resilience through high-quality innovation, strong data assets, recurring cash flows, and stable margins. In response to the transformative shifts reshaping the healthcare value chain, from drug discovery to care delivery, leading industry players are adopting bolder strategies to strategically reposition their portfolios.
A Glance at 2025
In 2025, the health industries witnessed a notable rebound in M&A activity following a subdued 2024. While overall transaction volumes remained low, a series of high-value megadeals drove total deal value back to levels comparable with the pre-pandemic period. This resurgence was primarily driven by major industry players acquiring smaller, innovation-driven companies with advanced assets, aiming to bolster their pipelines and expand portfolios with adjacent and complementary solutions.
„In Austria, health industries M&A remains selective but growth- and innovation-driven, with the country's research potential and strategic European positioning serving as attractive factors for investors and cross-border collaboration.“
Amra Ibric,PLS Deals Team Lead AustriaCapital markets and exit environment
While public market valuations are expected to remain volatile throughout 2026, early market indicators, which serve as proxies for company valuations, suggest a narrowing valuation gap at the year's outset, reflecting increasing alignment between market expectations and underlying technological fundamentals.
Both corporate and financial investors are gearing up for potentially favorable exit opportunities in the near term. As many financial investors approach the end of their holding periods, we anticipate a steady flow of divestitures and secondary transactions.
Although overall market activity has yet to fully rebound to pre-pandemic levels, IPO markets are expected to play an increasingly important role in providing viable exit routes. This is especially true for companies operating in AI-enabled care, digital platforms, and medtech, sectors that have attracted intensified interest from sponsors and crossover investors.
The mid-December 2025 Nasdaq debut of Medline, which raised $7.26 billion in the largest IPO in nearly five years, serves as a powerful indicator of this growing confidence, signaling a more robust and dynamic exit environment ahead.
Key global M&A hotspots in 2026: strategic drivers and considerations
The global M&A landscape in 2026 demonstrates a strategic push toward a more balanced distribution of innovation worldwide. Among the countries leading this transformation, China and India are emerging as influential players within the global ecosystem of pharmaceutical development.
China is strengthening its role as a central hub for life sciences innovation, backed by supportive regulatory reforms. Significant initiatives aimed at enhancing development processes and regulatory frameworks have increased China’s attractiveness for cross-border collaborations, reinforcing its significance in international M&A activities.
India is rapidly establishing itself as a vital life sciences market, attracting foreign investment through its advanced national digital health infrastructure. This infrastructure enables data-rich, AI-supported clinical workflows at scale, providing key differentiators for cross-border partners seeking operational efficiency, cost-effective supply chains, and access to a large patient base.
Sector-specific M&A priorities and trends
Sustained buyer vigilance, driven by prevailing political and economic factors, continues to favor deals with clear strategic alignment and predictable returns. Large pharmaceutical companies are addressing loss-of-exclusivity challenges by focusing on late-stage pipeline assets characterized by differentiated clinical data, transparent regulatory pathways, and commercial readiness.
Consequently, buyers emphasize derisked innovation, programs with validated efficacy, robust trial outcomes, and defined approval routes.
In medtech, portfolio optimization remains a priority, with companies divesting lower-growth or non-core assets to reinvest in faster-growing segments. Next-generation technologies, including robotics, AI-enhanced imaging, sensors, and home-based devices, are central to long-term strategies aligned with prevention and care-anywhere models. Acquirers increasingly seek targets that combine differentiated technology with integrated data, software, and service capabilities to support recurring revenue streams and enhance customer retention.
Across sectors, digital capabilities and artificial intelligence are foundational to M&A strategies aimed at accelerating R&D cycles and improving operational efficiencies in response to evolving market pressures.
The Austrian Perspective
Market dynamics and strategic positioning
In the last years, Austria has established itself as one of leading European hubs for life sciences, with a robust network of innovative clusters, research-intensive universities, and internationally active companies. The country’s strengths in cancer research, digital medicine, and sustainable bioprocesses present significant opportunities for growth through acquisitions.
Austria’s emphasis on education and talent development ensures a steady pipeline of skilled professionals, fostering partnerships that prioritize intellectual capital and continuous innovation. Centrally located within Europe, Austria offers strategic access to Western, Eastern, and Southern European markets, enhancing its potential for cross-border collaboration.
Austria’s M&A market characteristics and recent transactions
Austria’s M&A environment reflects the dynamics typical of specialized markets, where capital access and competition from larger regional players are key considerations. Nonetheless, the market remains dynamic and innovation-driven, bolstered by a strong scientific community and government policies supporting life sciences innovation.
Recent strategic transactions highlight this momentum: Swedish Orphan Biovitrum’s announced acquisition of Pint Pharma, DCC Healthcare Ltd’s purchase of Richard Bittner AG, Bruker Corp’s acquisition of Biocrates Life Sciences AG, and Baerlocher GmbH’s acquisition of Reploid Group AG all underscore ongoing investor interest in Austria’s scientific expertise and innovation ecosystem. Particularly notable were transactions in the veterinary clinics sector, with VHH Veterinaria Health Holding GmbH, owned by Danish Vetopia ApS, completing eight acquisitions in the Austrian market in 2025.
In Austria’s mid-size market segment, M&A activity continues at a measured pace amid evolving valuation expectations. While some market participants benchmark against recent-cycle valuations, others weigh macroeconomic factors, financing costs, and sector-specific dynamics. This has led to extended transaction timelines and some paused or restructured deals. As expectations increasingly align with underlying fundamentals, deal flow is expected to improve, though near-term activity is likely to remain selective.
Looking ahead, Austria’s healthcare and life sciences sectors are well-positioned to capitalize on global scientific advances while carefully navigating geopolitical and economic challenges. The country’s strategic geographical location adds an attractive dimension for investors, serving as a gateway within the broader European ecosystem.
Global M&A Industry Trends in Health and Life Sciences
Contact us
